Setback to Bharat Biotech: CDSCO panel rejects to approve Covaxin, seeks more data

Published On 2021-01-02 06:30 GMT | Update On 2021-01-02 06:30 GMT

New Delhi: The Subject Expert Committee of the Central Drug Standard Control Organisation on Friday has held that the data provided by Bharat Biotech for its coronavirus vaccine 'Covaxin' is not sufficient for grant of emergency use approval and has asked for more information, top sources said.

Earlier on Friday, the expert committee, which is tasked with vetting covid-19 vaccine proposals, recommended emergency licensure for the Serum Institute of India-manufactured 'Covishield'. It become the first vaccine to secure recommendation for emergency use in India.

The Pune-based Serum Institute has partnered with Oxford-AstraZeneca for conducting clinical trials and manufacturing 'Covishield' while Bharat Biotech has collaborated with the Indian Council of Medical Research (ICMR) for 'Covaxin'.

The committee had convened a meeting to take a call on the emergency use authorisation sought by the Serum Institute, Bharat Biotech and America's Pfizer for their coronavirus vaccines candidates.

Pfizer was the first one to apply for the accelerated approval on December 4, followed by the Serum Insstitute and Bharat Biotech on December 6 and 7, respectively.

The meeting comes a day before dry run of the vaccine is slated to commence in all the states and Union Territories to equip the administration in management of vaccine supply, storage and logistics including cold chain management.

The Central government plans to vaccinate nearly 30 crore people in the first phase of drive. It will be offered to one crore healthcare workers, along with 2 crore frontline and essential workers and 27 crore elderly, mostly above the age of 50 years with co-morbidities.

Article Source : IANS

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

MD Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Setback to Bharat Biotech: CDSCO panel rejects to approve Covaxin, seeks more data

Similar News

Gufic Biosciences appoints Rajesh Kaul as Senior President - Sparsh Cluster

Alembic buys UTI-focused Utility Therapeutics in USD 12 million deal

Biocon Biologics gets EU nod for bone disease treatments, including Osteoporosis, giant cell tumour of bone

Aurobindo Pharma arm gets marketing nod for Dazublys from European Commission

Lincoln Pharma to begin API production at Khatraj facility in 1- 2 years

Sun Pharma Gets CDSCO Panel Go-Ahead to Manufacture, Market Relugolix, Estradiol, Norethindrone Acetate FDC

Delhi HC Rejects Modi-Mundipharma's Monopoly Claim Over 'CONTIN', Allows Limited Relief

Natco Pharma sees major leadership exit in RnD, demand & supply, quality